Abstract Background Conventional diagnostic markers, such as eGFR or albuminuria, often detect established late stages of kidney disease missing early adaptive changes. Acylcarniti
A narrative review synthesizing evidence from multiple trials (FLOW, cardiovascular outcome trials) to position incretin-based therapies within the therapeutic landscape for CKD, without reporting a primary study result or meta-analysis.
A clinical consensus statement synthesizing evidence from trials (notably ISCHEMIA-CKD) to recommend a shift from protocol-driven to personalized cardiovascular screening in kidney transplant candidates.